
Real-world acne treatment adherence spans 6% to 84%, with cost, adverse effects, and slow results driving nonadherence.
An Arkansas judge slapped Johnson & Johnson and a subsidiary with more than $1.2 billion in penalties on Wednesday for deceptive marketing of the antipsychotic drug Risperdal.
The ruling marks the latest legal headache for J&J over the drug. Johnson & Johnson has faced lawsuits in a total of 11 states in connection with Risperdal.
Read the full story:
Source: CNN Money





